Skip to main content
Article thumbnail
Location of Repository

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

By J. Shepherd, J. Jones, Geoff Frampton, L. Tanajewski, D. Turner and A.M. Price


Objectives: To assess the clinical and cost-effectiveness of magnesium sulphate compared with sotalol, and to assess the clinical effectiveness of magnesium sulphate compared with placebo in the prevention of atrial fibrillation (AF) in patients who have had a coronary artery bypass graft (CABG).<br/><br/>Data sources: Major electronic databases were searched from December 2003 to May 2007.<br/><br/>Review methods: Selected studies were assessed, subjected to data extraction using a standard template and quality assessment using published criteria. A simple short-term economic model was developed, informed by a systematic review of economic evaluations and populated with data from a review of costing/resource-use studies and other published studies. The cost-effectiveness of magnesium sulphate as prophylaxis was estimated for a set of base-case assumptions and the robustness of these results was assessed using deterministic and probabilistic sensitivity analysis.<br/><br/>Results: Twenty-two papers met the inclusion criteria reporting 15 trials which all compared magnesium sulphate with placebo or control. They ranged in size from 15 to 176 patients randomised, and were conducted in Europe, the USA and Canada. The standard of reporting was generally poor, with details of key methodological attributes difficult to elucidate. No trials were identified that specifically aimed to compare magnesium sulphate with sotalol. Of 1070 patients in the pooled magnesium group, 230 (21%) developed postoperative AF, compared with 307 of 1031 (30%) patients in the placebo or (control) group. Meta-analysis using a fixed-effects model generated a pooled odds ratio (OR) that was significantly less than 1.0 [OR = 0.65, 95% confidence interval (CI) 0.53 to 0.79, test for overall effect p &lt; 0.0001], but with statistically significant heterogeneity (I2 = 63.4%, p = 0.0005). Two randomised controlled trials (RCTs) were notable as they had relatively lower ORs in favour of magnesium sulphate. When these were removed from the analyses the pooled OR remained statistically significant, but heterogeneity no longer remained significant. These two studies tended to impart a highly significant reduction in the odds of AF to whichever subgroup they were analysed in. When studies were ordered by total duration of prophylaxis, an apparent relationship between duration and odds of AF was evident, with decreasing odds of AF as duration of prophylaxis increased. This was confirmed by linear regression analysis (R2 = 0.743, p &lt; 0.001). When the data were grouped into three classes according to duration, a statistically significant intervention effect was only present for the longest duration (OR = 0.12, 95% CI 0.06 to 0.23, p = 0.00001). Statistically significant intervention effects were associated with the initiation of prophylaxis 12 hours or more before surgery (OR 0.26; 95% CI 0.16 to 0.44, test for overall effect p = 0.00001, fixed-effects model) and less than 12 hours before surgery or during the surgery itself (OR = 0.73, 95% CI 0.56 to 0.97, test for overall effect p = 0.03, fixed-effects model), but not when prophylaxis was initiated at the end of surgery or postsurgery (OR = 0.85, 95% CI 0.59, 1.22, p = 0.37, fixed-effects model). When studies were ordered by total dose of intravenous magnesium sulphate (&lt;25 g), the odds of AF were independent of the dose. A notable exception was that for a total dose of 9 g magnesium sulphate; here the odds of AF were significantly reduced relative to the control group, although this may be explained by the fact that these studies had excluded patients who were on antiarrhythmic drugs and so may have been at higher risk of AF. Sixty-three potentially relevant references about cost-effectiveness were identified, but no economic evaluations of intravenous magnesium alone as prophylaxis against AF following CABG, compared with sotalol as prophylaxis or no prophylaxis, were identified. Studies reporting resource use by patients with AF following CABG suggest that while AF significantly increased inpatient stays, by up to 2.3 days in the intensive care unit (ICU) and 3.4 days on the ward, differences in length of stay and costs between patients receiving prophylaxis and those not receiving prophylaxis were not statistically significant. In the base-case analysis, magnesium sulphate prophylaxis resulted in 0.081 fewer cases of AF at an incremental cost of £2.55. The incremental cost-effectiveness ratio (ICER) was £32 per AF case avoided. The estimated difference in average length of stay between the prophylaxis and no-prophylaxis strategies was only 0.24 days, despite a large assumed difference of 3 days for patients experiencing AF in each group (1 extra day in the ICU and 2 extra days on the ward). In a deterministic sensitivity analysis the greatest variation in ICERs was observed for input parameters relating to the baseline risk of AF following CABG and the effectiveness of prophylaxis, cost of prophylaxis and the resource consequences of postoperative AF. The largest ICER (£2092) in the sensitivity analysis was associated with increasing the length of patients' preoperative stay. In the base case it was assumed that admission routines would be identical under both strategies. However, patients receiving prophylaxis by intravenous infusion may have longer preoperative stays. In a probabilistic analysis the majority of the simulations were associated with improved outcomes (in this case fewer cases of AF), but also higher costs. Prophylaxis was the dominant strategy (better outcome at lower cost) in about 41% of the simulations using the base-case assumptions. Under an alternative scenario where patients receiving prophylaxis are admitted for longer before their operation, to receive their initial infusion, the proportion of simulations where prophylaxis dominates fell to around 5%. The probability of being cost-effective was 99% at a willingness to pay (WTP) threshold of £2000 per AF case avoided and 100% at a WTP threshold of £5000 per AF case avoided under the base-case assumptions. Under the alternative scenario of longer preoperative stays the probability of being cost-effective at these two threshold values fell to 48% and 93%, respectively. It is unclear what the appropriate decision threshold should be, given that this model used intermediate rather than final outcomes.<br/><br/>Conclusions: No RCTs were identified that specifically aimed to compare intravenous magnesium with sotalol as prophylaxis for AF in patients undergoing CABG. Intravenous magnesium, compared with placebo or control, is effective in preventing postoperative AF, as confirmed by a statistically significant intervention effect based on pooled analysis of 15 RCTs. It was also found that AF was less likely to occur when a longer duration of prophylaxis was used, and the earlier that prophylaxis is started; however, this finding was associated with two RCTs that had more favourable results than the other trials. No clear relationship between dose and AF was observed, although a lower constant dose rate was associated with the lowest odds of AF. Further research should investigate the relationship between dose, dose rate, duration of prophylaxis, timing of initiation of therapy and patient characteristics, such as degree of risk for AF. This will provide stronger evidence for the optimum delivery of intravenous magnesium in patients undergoing CABG. In the base-case analysis in the economic model, magnesium sulphate prophylaxis reduced the number of postoperative AF cases at a modest increase in cost. The results of the economic analysis are highly sensitive to variation in certain key parameters. Prophylaxis is less likely to be a cost-effective option if it requires changes in admission routines that result in longer preoperative stays than would be the case without prophylaxis

Topics: RS, RT
Year: 2008
OAI identifier:
Provided by: e-Prints Soton
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles


    1. (2001). 1 Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic
    2. (2008). 97 © Queen’s Printer and Controller of HMSO 2008. All rights reserved. Health Technology Assessment reports published to dateNo. 15 Ethical issues in the design and conduct of randomised controlled trials. A review by
    3. (2008). 99 © Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 34 A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. By MacLehose
    4. (2008). a Compared with placebo and/or sotalol.Health Technology Assessment
    5. (2000). A review by
    6. (2006). A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost–utility for these groups in a UK context. Health Technol Assess doi
    7. (2002). A study of the methods used to select review criteria for clinical audit. By Hearnshaw
    8. (2008). A systematic review and economic model of switching from nonglycopeptide to glycopeptide antibiotic prophylaxis for surgery.
    9. (2008). All rights reserved.Cochrane Library
    10. (2008). All rights reserved.No. 19 Clinical effectiveness and costeffectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic
    11. (2008). All rights reserved.No. 2 ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic doi
    12. (2008). All rights reserved.No. 4 A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. By Whiting doi
    13. (2008). All rights reserved.No. 5 A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. By doi
    14. (2008). All rights reserved.Volume 9,
    15. (2005). Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke doi
    16. Assessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines. doi
    17. (1998). Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay? Chest doi
    18. (1997). Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg doi
    19. (2000). Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification. Circulation doi
    20. authors would like to know your views about this report.
    21. (1995). Conflict of interests: None reported. ACE, angiotensin-converting enzyme.Appendix 3 72 Reference and Intervention Participants Outcome measures design Authors: Karmy-Jones et al.24 Year:
    22. (2003). Conflict of interests: None reported. BP , blood pressure.Appendix 3 70 Reference and Intervention Participants Outcome measures design Authors: Kaplan et al.23 Year:
    23. (1991). Conflict of interests: None reported.Appendix 3 64 Reference and Intervention Participants Outcome measures design Authors: Fanning et al.19 Year:
    24. (2008). Conflict of interests: None reported.Health Technology Assessment
    25. (1996). Conflict of interests: Not reported.Appendix 3 74 Reference and Intervention Participants Outcome measures design Authors: Nurözler et al.25 Year:
    26. Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)]. doi
    27. Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation doi
    28. (1997). Effectiveness of digitalis with or without acebutolol in preventing atrial arrhythmias after coronary artery surgery. doi
    29. Efficacy of sotalol and magnesium in the prevention of atrial fibrillation following coronary artery bypass surgery.
    30. (2003). How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical
    31. (2004). Intercentre variability: NA Conflict of interests: None reported. SVA, supraventricular arrhythmia.Appendix 3 68 Reference and Intervention Participants Outcome measures design Authors: Hazelrigg et al.22 Year:
    32. (2006). Intervention Participants Outcome measures design Authors: Bhudia et al.16 Year:
    33. (1995). Intervention Participants Outcome measures design Authors: Caspi et al.13 Year:
    34. (2002). Intervention Participants Outcome measures design Authors: Dagdelen et al.17,18a Year:
    35. (2002). Intervention Participants Outcome measures design Authors: Forlani et al.20,21a Year:
    36. (1993). Intervention Participants Outcome measures design Authors: Parikka et al.26 Year:
    37. (2001). Intervention Participants Outcome measures design Authors: Toraman et al.27 Year:
    38. (2000). Intervention Participants Outcome measures design Authors: TreggiariVenzi et al.28 Year:
    39. (2000). Intervention Participants Outcome measures design Authors: Yilmaz et al.14 Year:
    40. (2005). Intervention Participants Outcome measures design Authors: Zangrillo et al.29 Year:
    41. (2006). London: Royal College of Physicians; doi
    42. (2008). mass index; COPD, chronic obstructive pulmonary diseases; NYHA, New York Heart Association; PVD, peripheral vascular disease.Health Technology Assessment
    43. (2007). No. 1 Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. By Dundar
    44. (2006). No. 1 The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. By Loveman E, doi
    45. (1980). Organisation for Economic Cooperation and Development. Purchasing power parities (PPPs) for OECD countries since
    46. (2008). Other outcomes Outside scope of assessment: data not extracted continuedHealth Technology Assessment
    47. (2006). Patterns of atrial fibrillation after coronary artery bypass surgery. Ann Noninvasive Electrocardiol doi
    48. (2008). Postoperative ST segment elevation was significantly less frequent in the magnesium group. Postoperative creatinine kinase concentration was significantly lower in the magnesium group continuedHealth Technology Assessment
    49. Predictors of atrial fibrillation after off-pump coronary artery bypass graft surgery. doi
    50. (1991). Register #1. magnesium 197 #2. (atrial next fibrillat*) 442 #3. ((coronary or heart or atri*) and surgery
    51. Resource utilization related to atrial fibrillation after coronary artery bypass grafting. doi
    52. (2003). Society for Cardiothoracic Surgery of Great Britain and Ireland. Fifth National Adult Cardiac Surgical Database Report
    53. (2000). Society for Cardiothoracic Surgery of Great Britain and Ireland. National Adult Cardiac Surgical Database
    54. Stroke after coronary artery bypass: incidence, predictors, and clinical outcome editorial comment: Incidence, predictors, and clinical outcome. doi
    55. (1997). The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery. Heart doi
    56. (2008). The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA preliminary model-based assessment of the cost–utility of a screening programme for early age-related macular degeneration doi
    57. (2008). ventricular ejection fraction; MI, myocardial infarction; ns, not significant; POAT, postoperative atrial tachycardia; SVT, supraventricular tachycardia.Health Technology Assessment
    58. (2004). What is the best imaging strategy for acute stroke? By

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.